Ambrx lands $52M in funds
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
Ambrx
|
$52M
|
Apposite |
Ambrx is developing biopharmaceuticals based on protein modification. |
|
Alder Biopharmaceuticals
|
$16M
|
H.I.G. Ventures |
Alder is advancing its antibody therapeutics program. |
|
Ocera Therapeutics
|
$12M
|
Sofinnova Ventures |
Ocera is developing a product to fight Crohn's Disease. |
|
IVREA Pharmaceuticals
|
$11M
|
Atlas Venture, Easton Capital, CHL Medical Partners |
IVREA, which focuses is dermatology, is using the funds for clinical development. |